Recent developments highlight the company’s progress in advancing ATH434 into Phase 3 clinical trials for Multiple System Atrophy, with FDA backing and Fast Track designation. The company has also made key appointments and completed important clinical milestones.

• Alterity announced plans to initiate the Phase 3 trial of ATH434 in MSA following receipt of End of Phase 2 minutes from the FDA [N1].
• The company aligned with the FDA on the Phase 3 design for ATH434 in treating Multiple System Atrophy [N3].
• Alterity received positive FDA feedback on the ATH434 Phase 3 study [N4].
• The company gained FDA backing for the Phase 3 MSA trial [N5].
• Alterity secured FDA Fast Track designation for ATH434 for MSA treatment [N8].
• The company completed the last patient visit in the ATH434-202 Phase 2 trial for MSA [N7].
• Alterity appointed Daniel Claassen as Chief Medical Advisor [N6].

The company has advanced its lead candidate ATH434 into Phase 3 clinical trials with FDA backing and Fast Track designation, indicating regulatory support and potential for expedited development. Successful clinical outcomes could validate its therapeutic approach for MSA, a disease with significant unmet medical need. The company’s strong liquidity position and recent equity funding provide resources to support ongoing R&D activities. Strategic appointments, such as the Chief Medical Advisor, may enhance clinical development expertise.

Alterity Therapeutics faces typical risks of development-stage biotech companies, including the high probability of clinical trial failure, regulatory hurdles, and the need for substantial additional capital to fund operations. The company has incurred significant losses and operating cash outflows, which may continue. Its business model depends on successful clinical development and eventual commercialization, which remain uncertain. Market and economic conditions in Australia and currency fluctuations may also impact operations and financial results.

Alterity Therapeutics operates in the highly specialized and competitive biotechnology sector focused on neurodegenerative diseases. Its moat is primarily based on its proprietary drug candidates, particularly ATH434, and its intellectual property portfolio, which has been expanding through new patent applications. The company’s regulatory progress, including FDA Fast Track designation and Phase 3 trial alignment, adds to its competitive positioning. However, as a development-stage company without marketed products, its moat is contingent on successful clinical development and regulatory approvals.

• Clinical Development Risk: All product candidates are in early to mid-stage development, facing inherent risks of failure in clinical trials and regulatory approval processes.
• Capital Requirements: The company has incurred recurring losses and operating cash outflows, requiring substantial additional capital to continue R&D programs and operations.
• Regulatory Risk: Progress depends on regulatory approvals and compliance, with potential delays or negative outcomes impacting development timelines.
• Market and Economic Conditions: Being incorporated and operating primarily in Australia exposes the company to political, economic, and currency risks specific to that region.

• Alterity Therapeutics Ltd is a development-stage medical biotechnology company focused on pharmaceutical products targeting neurodegeneration of the brain.
• The company is incorporated in Australia and reports in Australian dollars.
• All product candidates are in discovery or early to mid-stage development phases.
• The company has incurred net losses since inception, including a net loss of AUD 23,400,949 for the year ended June 30, 2026, and operating cash outflow of AUD 22,523,333 for the same period.
• Research and development expenses increased to AUD 17,629,577 for the year ended June 30, 2026, reflecting initiation of new R&D studies.
• General and administrative expenses increased to AUD 10,528,013 for the year ended June 30, 2026, mainly due to staffing, audit, and consulting costs.
• Intellectual property expenses increased to AUD 262,778 for the year ended June 30, 2026, mainly due to new patent applications.
• The company raised new equity funding during the 2026 financial year to support R&D programs for at least the next 12 months.
• Liquidity as of June 30, 2025, included cash and equivalents of AUD 33,158,642, current assets of AUD 45,871,186, and current liabilities of AUD 3,534,729, resulting in a current ratio of 12.98 and cash ratio of 9.38.
• The company has received FDA backing and positive feedback for its Phase 3 clinical trial design of ATH434 for treating Multiple System Atrophy (MSA).
• Alterity secured FDA Fast Track designation for ATH434 for MSA treatment.
• The company announced plans to initiate the Phase 3 trial of ATH434 in MSA following receipt of End of Phase 2 (EOP2) minutes from the FDA.
• Alterity appointed Daniel Claassen as Chief Medical Advisor.
• The company has completed the last patient visit in the ATH434-202 Phase 2 trial for MSA.
• The company funds operations primarily through equity sales, option exercises, government grants, licensing, research collaborations, and interest income.
• Interest income increased significantly in the year ended June 30, 2026, due to higher cash balances.
• The company faces risks typical of development-stage biotech firms, including the need for substantial additional capital, regulatory approval risks, and the inherent risks of drug development.
• The company’s consolidated financial statements are prepared assuming it will continue as a going concern based on recent funding.
• The company’s revenues are generated in Australian dollars, with most expenses also in AUD, except for interest earned on foreign currency accounts.